SCHEMBL6897029

SCHEMBL6897029

CCOC(=O)C=C(c1cccc(OC)c1)c1cccc(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.54
CES1 P23141 1/20 0.54
MTNR1A P48039 3/20 0.53
MTNR1B P49286 3/20 0.53
PARP1 P09874 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
ALDH1A1 P00352 2/20 0.51
MAPT P10636 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
TSHR P16473 2/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PDE4A P27815 3/20 0.48
PDE4B Q07343 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779941 0.88 OPRD1 (0.53) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL6779935 0.88 OPRD1 (0.53) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL11486614 0.87 CES2 (0.53) CES2CES1MTNR1AMTNR1BPARP1
SCHEMBL11486610 0.87 CES2 (0.53) CES2CES1MTNR1AMTNR1BPARP1
SCHEMBL15275783 0.86 PARP1 (0.56) CES2CES1MTNR1AMTNR1BPARP1
SCHEMBL7550000 0.85 RAB9A (0.52) CES2CES1MTNR1AMTNR1BSMN1; SMN2
SCHEMBL15280988 0.83 CES2 (0.49) CES2CES1MTNR1AMTNR1BPARP1
SCHEMBL10398950 0.83 ALDH1A1 (0.50) CES2CES1MTNR1AMTNR1BPARP1
SCHEMBL11762780 0.83 CES2 (0.49) CES2CES1MTNR1AMTNR1BPARP1
SCHEMBL10397713 0.83 ALDH1A1 (0.50) CES2CES1MTNR1AMTNR1BPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6703504-B2 HAVING SUBSTANTIAL ORIENTATIONAL RIGIDITY OF AROMATIC RINGS WITH RESPECT TO CENTRAL INDANE MOIETY AND ELECTRON DONATING FUNCTIONALITY WHICH PROMINENTLY ACTIVATES AND ACCELERATES ELECTROPHILIC AROMATIC SUBSTITUTION OF PARENT RINGS Slemon, Clarke (CA) 2004-03-09 US disclosed
US-20030232932-A1 Conformationally constrained compounds as dendrimer cores SLEMON, CLARKE (CA) 2003-12-18 US disclosed
WO-1994025427-A1 ETHANOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232932-A1 Conformationally constrained compounds as dendrimer cores PCNA, PICALM, CROCC CES2 3669/4885CES1 4830/4885MTNR1A 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.